Reimbursement authority NICE published draft guidance today giving a green light to the use of Columvi (glofitamab) in ...
The survival rate of frozen eggs and embryos reaches more than 90% in good in vitro fertilization labs when a patient is ...
Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a ...
New data from cohort 3 show EO2463 can be safely added to rituximab in first-line low-tumor-burden follicular lymphoma in need of treatment; All six patients responded positively ...
The drug given every three weeks via an intravenous infusion will be available from today thanks to the NHS fast-tracking access through its Cancer Drugs Fund, which provides patients with quicker ...
ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for ...
In this video, Paolo Strati, MD, discusses two clinically impactful phase 2 studies that evaluated the safety and efficacy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback